2 not yet recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow NF2: new trials by email Literature Review of NF2 trials Research Report on NF2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
Neurofibromatosis 2 (2) · Meningioma (1) · Neuroma, Acoustic (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Cranial Nerve Diseases (2) · Cranial Nerve Neoplasms (2) · Ear Diseases (2) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neoplastic Syndromes, Hereditary (2) · Nerve Sheath Neoplasms (2) · Nervous System Diseases (2) · Neurilemmoma (2) · Neurocutaneous Syndromes (2)
Beijing Tiantan Hospital (1) · PRG Science & Technology Co., Ltd. (1)
China (1)